Novo Nordisk and Hims & Hers have ended a legal feud with an agreement that allows the telehealth platform to sell the pharma giant’s blockbuster brand-name GLP-1 drugs. In separate statements issued ...

Novo Nordisk has decided to withdraw its patent infringement lawsuit against Hims & Hers Health, following an agreement that will allow the telehealth company to sell Novo Nordisk's branded weight ...

Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...

Health-care companies rose as a distribution spat was resolved. Wegovy maker Novo Nordisk said it was teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company's ...

COPENHAGEN, March 9 (Reuters) - Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers Health platform, ending a legal ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk's branded weight loss ...

In early March, Hims & Hers resolved a patent dispute with Novo Nordisk. As part of this settlement, the platform is now integrating original drugs such as Ozempic and Wegovy into its offerings. This ...

Wegovy maker Novo Nordisk said it is teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company’s platform, bringing an end to a legal dispute between the two ...

The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...